Novavax

About:

Novavax is a biotechnology company that focuses on the discovery and development of innovative vaccines for various infectious diseases.

Website: http://www.novavax.com

Twitter/X: novavaxinc

Top Investors: RA Capital Management, Bill & Melinda Gates Foundation, SK Bioscience, Government of United States of America, Coalition for Epidemic Preparedness Innovations

Description:

Novavax is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated the development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’s proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.